PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSStandard ALS Measure ALSFRS-R already demonstrated a statistically.
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE - NeuroSense Therapeutics Ltd. , a company developing treatments for severe neurodegenerative diseases, today reported that it met its primary safety and tolerability endpoints and.
Neurosense Therapeutics' (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at three upcoming conferences.